TEE
CBMG

Tibra Equities Europe’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Tibra Equities Europe’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-27,777
Closed -$487K – 247
2018
Q1 		$487K Buy
+27,777
New +$508K 0.09% 124

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Tibra Equities Europe's CBMG Position: Q2 2018 in Review

Tibra Equities Europe sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2018, closing a stake of 27,777 shares — an estimated $487K sold.

Tibra Equities Europe first reported a position in CBMG in Q1 2018 and held it in 1 quarter. The position peaked at $487K in Q1 2018. 34 funds tracked by Wall St. Rank hold CBMG as of Q2 2018.

  • Tibra Equities Europe reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2018 after selling out during the quarter.
  • Tibra Equities Europe sold 27,777 Cellular Biomedicine Group, Inc. shares in Q2 2018, an estimated $487K.
  • Tibra Equities Europe first reported a position in Cellular Biomedicine Group, Inc. in Q1 2018 and held it in 1 quarter.
  • Tibra Equities Europe's Cellular Biomedicine Group, Inc. position peaked at $487K in Q1 2018.
  • 34 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2018.

Based on Tibra Equities Europe's 13F filing for Q2 2018, filed 10 Aug 2018.